PL3074011T3 - Połączone fuzyjnie oktahydro związki azadekaliny jako modulatory receptora glukokortykoidowego - Google Patents
Połączone fuzyjnie oktahydro związki azadekaliny jako modulatory receptora glukokortykoidowegoInfo
- Publication number
- PL3074011T3 PL3074011T3 PL14863514T PL14863514T PL3074011T3 PL 3074011 T3 PL3074011 T3 PL 3074011T3 PL 14863514 T PL14863514 T PL 14863514T PL 14863514 T PL14863514 T PL 14863514T PL 3074011 T3 PL3074011 T3 PL 3074011T3
- Authority
- PL
- Poland
- Prior art keywords
- fusionally
- octahydro
- modulators
- joined
- glucocorticoid receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908333P | 2013-11-25 | 2013-11-25 | |
| US201461985035P | 2014-04-28 | 2014-04-28 | |
| PCT/US2014/066759 WO2015077530A1 (en) | 2013-11-25 | 2014-11-21 | Octahydro fused azadecalin glucocorticoid receptor modulators |
| EP14863514.7A EP3074011B1 (en) | 2013-11-25 | 2014-11-21 | Octahydro fused azadecalin glucocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3074011T3 true PL3074011T3 (pl) | 2020-01-31 |
Family
ID=53180165
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21158231.7T PL3848027T3 (pl) | 2013-11-25 | 2014-11-21 | Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego |
| PL14863514T PL3074011T3 (pl) | 2013-11-25 | 2014-11-21 | Połączone fuzyjnie oktahydro związki azadekaliny jako modulatory receptora glukokortykoidowego |
| PL19177963T PL3560493T3 (pl) | 2013-11-25 | 2014-11-21 | Skondensowane oktahydroazadekaliny będące modulatorami receptora glukokortykoidowego |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21158231.7T PL3848027T3 (pl) | 2013-11-25 | 2014-11-21 | Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19177963T PL3560493T3 (pl) | 2013-11-25 | 2014-11-21 | Skondensowane oktahydroazadekaliny będące modulatorami receptora glukokortykoidowego |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US10047082B2 (OSRAM) |
| EP (4) | EP3848027B1 (OSRAM) |
| JP (6) | JP6516743B2 (OSRAM) |
| KR (1) | KR102352737B1 (OSRAM) |
| CN (2) | CN109761976B (OSRAM) |
| AU (1) | AU2014352915B2 (OSRAM) |
| BR (1) | BR112016011826B1 (OSRAM) |
| CA (1) | CA2931302C (OSRAM) |
| DK (2) | DK3074011T3 (OSRAM) |
| ES (3) | ES2869172T3 (OSRAM) |
| FI (1) | FI3848027T3 (OSRAM) |
| IL (1) | IL245848B (OSRAM) |
| MX (1) | MX368167B (OSRAM) |
| MY (1) | MY180141A (OSRAM) |
| PH (1) | PH12016500968B1 (OSRAM) |
| PL (3) | PL3848027T3 (OSRAM) |
| PT (2) | PT3074011T (OSRAM) |
| RU (1) | RU2674983C1 (OSRAM) |
| WO (1) | WO2015077530A1 (OSRAM) |
| ZA (1) | ZA201604026B (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| BR112016011826B1 (pt) * | 2013-11-25 | 2022-09-27 | Corcept Therapeutics, Inc | Composto, composição farmacêutica e uso do referido composto |
| AU2016243625B2 (en) | 2015-03-30 | 2020-09-10 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
| IL297201A (en) | 2016-03-01 | 2022-12-01 | Corcept Therapeutics Inc | Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors |
| CN106478464B (zh) * | 2016-08-30 | 2018-06-05 | 黄河三角洲京博化工研究院有限公司 | 一种2-氟-6-三氟甲基苯磺酰氯的制备方法 |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| WO2018165460A1 (en) | 2017-03-09 | 2018-09-13 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors |
| PT3600282T (pt) | 2017-03-31 | 2025-11-05 | Corcept Therapeutics Inc | Moduladores de recetores de glucocorticoides para tratar cancro cervical |
| WO2018209142A2 (en) * | 2017-05-10 | 2018-11-15 | Corcept Therapeutics, Inc. | Octahydro azadecalin formulations |
| EP3641780B1 (en) | 2017-06-20 | 2025-09-10 | Corcept Therapeutics Incorporated | Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators |
| EP3773524B1 (en) * | 2018-04-10 | 2025-04-09 | Duke University | Lasofoxifene for the treatment of er+ breast cancer carrying the mutation d538g or y537s |
| ES3038908T3 (en) * | 2018-04-23 | 2025-10-15 | Corcept Therapeutics Inc | Methods of preparing regioselective n-alkyl triazoles |
| AR117951A1 (es) * | 2018-07-20 | 2021-09-08 | Gruenenthal Gmbh | Derivados de triazolquinoxalina adicionalmente sustituidos |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| CN117281790A (zh) | 2018-12-19 | 2023-12-26 | 科塞普特治疗公司 | 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂 |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CA3131263C (en) * | 2019-02-22 | 2024-01-02 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| EP4045045A4 (en) | 2019-10-16 | 2023-11-22 | Corcept Therapeutics Incorporated | METHOD FOR NORMALIZING THE RATIO BETWEEN NEUTROPHILS AND LYMPHOCYTES IN CANCER PATIENTS USING A SELECTIVE GLUCOCORTICOID RECEPTOR ANTAGONIST |
| WO2021119432A1 (en) | 2019-12-11 | 2021-06-17 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| US20230358768A1 (en) | 2019-12-21 | 2023-11-09 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
| WO2021154750A1 (en) | 2020-01-29 | 2021-08-05 | Corcept Therapeutics Incorporated | TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS |
| KR20220140567A (ko) * | 2020-02-10 | 2022-10-18 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 선택적 글루코코르티코이드 수용체 조절제를 사용하여 항-종양 반응을 자극하는 방법 |
| WO2021262587A1 (en) | 2020-06-22 | 2021-12-30 | Corcept Therapeutics Incorporated | Quaternary indazole glucocorticoid receptor antagonists |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| CN116829556A (zh) * | 2021-02-03 | 2023-09-29 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| JP2025501553A (ja) | 2021-12-21 | 2025-01-22 | コーセプト セラピューティクス， インコーポレイテッド | 二環式インダゾールグルココルチコイド受容体拮抗薬 |
| WO2023122600A1 (en) | 2021-12-21 | 2023-06-29 | Corcept Therapeutics Incorporated | Piperazine indazole glucocorticoid receptor antagonists |
| EP4598513A1 (en) | 2022-10-06 | 2025-08-13 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| EP4608402A1 (en) | 2022-10-28 | 2025-09-03 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| CN120752040A (zh) * | 2023-02-17 | 2025-10-03 | 科赛普特治疗学股份有限公司 | 用于治疗亨廷顿舞蹈症及其症状的方法和组合物 |
| US20240390341A1 (en) * | 2023-05-22 | 2024-11-28 | Corcept Therapeutics Incorporated | Methods for treating adrenal gland tumors |
| WO2025152964A1 (en) * | 2024-01-15 | 2025-07-24 | Insilico Medicine Ip Limited | Novel compounds as glucocorticoid receptor modulators and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS322220B1 (OSRAM) | 1954-11-30 | 1957-04-11 | ||
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| IL72729A (en) | 1983-09-26 | 1988-02-29 | Lilly Co Eli | Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them |
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP3160941B2 (ja) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | カルバゾール誘導体および免疫抑制剤 |
| FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| CA2168853A1 (en) | 1993-08-06 | 1995-02-16 | Giulio Dondio | Hydroisoquinoline derivatives |
| CA2683097A1 (en) | 1998-03-10 | 1999-09-16 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| EP1629845A3 (en) * | 2000-11-02 | 2006-03-22 | Akzo Nobel N.V. | Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| US7238778B2 (en) | 2001-07-17 | 2007-07-03 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| WO2003009853A1 (en) * | 2001-07-23 | 2003-02-06 | Corcept Therapeutics, Inc. | Methods for preventing antipsychotic-induced weight gain |
| US6679935B2 (en) * | 2001-08-14 | 2004-01-20 | Apex Advanced Technologies, Llc | Lubricant system for use in powdered metals |
| CA2473886C (en) | 2002-01-22 | 2012-08-21 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| BRPI0414066A (pt) | 2003-09-03 | 2006-10-24 | Wyeth Corp | 42-éster de rapamicina amorfo com ácido 3-hidróxi-2-( hidroximetil )-2-metilproipiÈnico e composições farmacêuticas que o contenha |
| EP1761497B1 (en) | 2004-01-09 | 2008-09-03 | Corcept Therapeutics, Inc. | Azadecalin glucocorticoid receptor modulators |
| PT1735308E (pt) * | 2004-03-09 | 2008-12-02 | Corcept Therapeutics Inc | Moduladores dos receptores de glucocorticóides de azadecalina de anel fundido |
| AU2006232660B2 (en) * | 2005-04-05 | 2010-03-25 | F. Hoffmann-La Roche Ag | 1H-Pyrazole 4-Carboxylamides, their preparation and their use as 11Beta-hydroxysteroid dehydrogenase |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| EP2209780B1 (en) * | 2007-11-01 | 2014-01-01 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof |
| EP2247597A1 (en) * | 2008-02-07 | 2010-11-10 | Bristol-Myers Squibb Company | Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
| EP2429529B1 (en) | 2009-05-12 | 2015-01-14 | Corcept Therapeutics, Inc. | Solid forms and process for preparing |
| US8710035B2 (en) * | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| BR112013004322A2 (pt) * | 2010-08-27 | 2016-06-21 | Corcept Therapeutics Inc | moduladores de azadecalin fundidos com piridil-aminas |
| US8829024B2 (en) | 2011-01-07 | 2014-09-09 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| US20130225633A1 (en) | 2012-02-27 | 2013-08-29 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| PL3590517T3 (pl) * | 2012-05-25 | 2021-09-20 | Corcept Therapeutics Incorporated | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| BR112016011826B1 (pt) * | 2013-11-25 | 2022-09-27 | Corcept Therapeutics, Inc | Composto, composição farmacêutica e uso do referido composto |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
-
2014
- 2014-11-21 BR BR112016011826-0A patent/BR112016011826B1/pt active IP Right Grant
- 2014-11-21 PL PL21158231.7T patent/PL3848027T3/pl unknown
- 2014-11-21 DK DK14863514.7T patent/DK3074011T3/da active
- 2014-11-21 PT PT14863514T patent/PT3074011T/pt unknown
- 2014-11-21 US US14/549,885 patent/US10047082B2/en active Active
- 2014-11-21 ES ES19177963T patent/ES2869172T3/es active Active
- 2014-11-21 PT PT211582317T patent/PT3848027T/pt unknown
- 2014-11-21 PL PL14863514T patent/PL3074011T3/pl unknown
- 2014-11-21 CN CN201910143177.XA patent/CN109761976B/zh active Active
- 2014-11-21 EP EP21158231.7A patent/EP3848027B1/en active Active
- 2014-11-21 CN CN201480074087.5A patent/CN106029066B/zh active Active
- 2014-11-21 CA CA2931302A patent/CA2931302C/en active Active
- 2014-11-21 AU AU2014352915A patent/AU2014352915B2/en active Active
- 2014-11-21 ES ES14863514T patent/ES2743620T3/es active Active
- 2014-11-21 EP EP19177963.6A patent/EP3560493B1/en active Active
- 2014-11-21 WO PCT/US2014/066759 patent/WO2015077530A1/en not_active Ceased
- 2014-11-21 EP EP23157691.9A patent/EP4219494A1/en active Pending
- 2014-11-21 DK DK21158231.7T patent/DK3848027T3/da active
- 2014-11-21 PL PL19177963T patent/PL3560493T3/pl unknown
- 2014-11-21 ES ES21158231T patent/ES2943542T3/es active Active
- 2014-11-21 KR KR1020167017023A patent/KR102352737B1/ko active Active
- 2014-11-21 FI FIEP21158231.7T patent/FI3848027T3/fi active
- 2014-11-21 RU RU2016123449A patent/RU2674983C1/ru active
- 2014-11-21 MX MX2016006725A patent/MX368167B/es active IP Right Grant
- 2014-11-21 MY MYPI2016000978A patent/MY180141A/en unknown
- 2014-11-21 JP JP2016533614A patent/JP6516743B2/ja active Active
- 2014-11-21 EP EP14863514.7A patent/EP3074011B1/en active Active
-
2016
- 2016-05-24 PH PH12016500968A patent/PH12016500968B1/en unknown
- 2016-05-25 IL IL245848A patent/IL245848B/en active IP Right Grant
- 2016-06-14 ZA ZA2016/04026A patent/ZA201604026B/en unknown
-
2017
- 2017-10-25 JP JP2017206081A patent/JP2018012734A/ja active Pending
-
2018
- 2018-07-16 US US16/036,001 patent/US20190135805A1/en not_active Abandoned
- 2018-10-16 US US16/161,642 patent/US10323034B2/en active Active
-
2019
- 2019-03-28 JP JP2019063279A patent/JP2019094355A/ja not_active Withdrawn
- 2019-04-12 US US16/382,474 patent/US10787449B2/en active Active
-
2020
- 2020-08-04 US US16/984,914 patent/US11370789B2/en active Active
-
2021
- 2021-01-12 US US17/146,608 patent/US11560379B2/en active Active
- 2021-02-15 JP JP2021021630A patent/JP2021073315A/ja not_active Withdrawn
-
2022
- 2022-11-28 JP JP2022189246A patent/JP2023011052A/ja not_active Withdrawn
- 2022-12-09 US US18/078,389 patent/US12139486B2/en active Active
-
2024
- 2024-08-30 JP JP2024148322A patent/JP2024170470A/ja active Pending
- 2024-10-04 US US18/906,346 patent/US20250034140A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3074011T3 (pl) | Połączone fuzyjnie oktahydro związki azadekaliny jako modulatory receptora glukokortykoidowego | |
| IL259738B (en) | Crystalline forms of an androgen receptor modulator | |
| DK3851107T3 (da) | Heteroaryl-ketonkondenseret azadecalin som glucocorticoidreceptormodulatorer | |
| HUE042443T2 (hu) | GPR6 tetrahidropiridopirazin-modulátorai | |
| DK3178817T3 (da) | Amorf form af tetracyklisk forbindelse | |
| BR112016012511A2 (pt) | acoplamento de anel fendido | |
| DK3783011T5 (da) | Aktivering af bioluminescens via strukturel komplementering | |
| BR112016003454A2 (pt) | Uso de composto de metil bardoxolona | |
| DK2948548T4 (da) | Fremgangsmåde til specifik isolering af nukleinsyrer af interesse | |
| DK3010895T3 (da) | Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner | |
| SMT201700009B (it) | Modulatori del recettore x del fegato | |
| DK3014279T3 (da) | Fremgangsmåde til bestemmelse af proteinaggregater under anvendelse af overflade-fida | |
| DK2964229T3 (da) | Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren | |
| SMT201600374B (it) | Modulatori del recettore x del fegato | |
| DK3221333T3 (da) | 6-alfa-alkyl-3,7-dionsteroider som mellemprodukter til fremstilling af steroide FXR-modulatorer | |
| HRP20181596T1 (hr) | Tiazolopirimidinoni kao modulatori aktivnosti nmda receptora | |
| HRP20181122T1 (hr) | Postupak za pripremu jopamidola | |
| DK3022174T3 (da) | Derivater af n-urinstof-substituerede aminosyrer som formylpeptidreceptormodulatorer | |
| EP2967073A4 (en) | LXR MODULATORS | |
| HUE063095T2 (hu) | Eljárások pirimidinilciklopentán vegyületek elõállítására | |
| EP2945852A4 (en) | LINKING AGENTS | |
| DK3083976T3 (da) | Fremgangsmåde til fremstilling af tiacumicin b | |
| TH1401005255B (th) | สารผสมของสารยึดติดโพลีโอเลฟิน | |
| ES1086233Y (es) | Soporte ecologico dispensador de ceniceros | |
| TH1401007292A (th) | รูปแบบผลึกของแอนโดรเจนรีเซปเตอร์มอดูเลเตอร์ |